Page last updated: 2024-12-08
tolmetin glycinamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 135911 |
| SCHEMBL ID | 3051890 |
| MeSH ID | M0162151 |
Synonyms (19)
| Synonym |
|---|
| mcn-4366 |
| unii-3rs348sv6u |
| glycine, n-((1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetyl)- |
| tolmetin glycine amide |
| 3rs348sv6u , |
| tolmetin glycineamide |
| tolmetin glycinamide |
| 2-[[2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetyl]amino]acetic acid |
| 87344-05-6 |
| AKOS015901744 |
| glycine, n-(2-(1-methyl-5-(4-methylbenzoyl)-1h-pyrrol-2-yl)acetyl)- |
| n-((1-methyl-5-p-toluoylpyrrol-2-yl)acetyl)glycine |
| mcn 4366 |
| amtolmetin |
| SCHEMBL3051890 |
| DTXSID90236290 |
| (s)-3-acetoxy-4-bromobutyrylchloride |
| Q27257950 |
| {2-[1-methyl-5-(4-methyl-benzoyl)-1h-pyrrol-2-yl]-acetylamino}-acetic acid |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "It may be concluded that BCRP plays an important role in the intestinal efflux of MED-5 and limits the bioavailability after oral administration of MED-15." | ( Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability. Li, X; Liu, D; Rong, Z; Xiang, D; Xu, Y; Zhang, C, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||